nach oben

Erschienen in:

01.04.2014 | Article

Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007–2011

verfasst von: Frank G. A. Assogba, Cécile Couchoud, Thierry Hannedouche, Emmanuel Villar, Luc Frimat, Anne Fagot-Campagna, Christian Jacquelinet, Bénédicte Stengel, on behalf of the French Renal Epidemiology and Information Network (REIN) Registry

Erschienen in: Diabetologia | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The aim was to study geographic variations and recent trends in the incidence of end-stage renal disease (ESRD) by diabetes status and type, and in patient condition and modalities of care at initiation of renal replacement therapy.

Methods

Data from the French population-based dialysis and transplantation registry of all ESRD patients were used to study geographic variations in 5,857 patients without diabetes mellitus, 227 with type 1 diabetes mellitus, and 3,410 with type 2. Trends in incidence and patient care from 2007 to 2011 were estimated.

Results

Age- and sex-adjusted incidence rates were higher in the overseas territories than in continental France for ESRD unrelated to diabetes and related to type 2 diabetes, but quite similar for type 1 diabetes-related ESRD. ESRD incidence decreased significantly over time for patients with type 1 diabetes (−10% annually) and not significantly for non-diabetic patients (0.2%), but increased significantly for patients with type 2 diabetes (+7% annually until 2009 and seemingly stabilised thereafter). In type 2 diabetes, the net change in the absolute number was +21%, of which +3% can be attributed to population ageing, +2% to population growth and +16% to the residual effect of the disease. Patients with type 2 diabetes more often started dialysis as an emergency (32%) than those with type 1 (20%) or no diabetes.

Conclusions/interpretation

The major impact of diabetes on ESRD incidence is due to type 2 diabetes mellitus. Our data demonstrate the need to reinforce strategies for optimal management of patients with diabetes to improve prevention, or delay the onset, of diabetic nephropathy, ESRD and cardiovascular comorbidities, and to reduce the rate of emergency dialysis.

Nur mit Berechtigung zugänglich

Kramer A, Stel V, Zoccali C et al (2009) An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 24:3557–3566PubMedCrossRef

Grace BS, Clayton P, McDonald SP (2012) Increases in renal replacement therapy in Australia and New Zealand: understanding trends in diabetic nephropathy. Nephrology (Carlton) 17:76–84CrossRef

Foley RN, Collins AJ (2007) End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 18:2644–2648PubMedCrossRef

US Renal Data System (2012) USRDS 2012 annual data report: atlas of end-stage renal disease in the United States. Available from www.usrds.org/2012/view/default.aspx, accessed 18 July 2013

Canadian Institute for Health Information (2011) Annual report: treatment of end-stage organ failure in Canada, 2001 to 2010. Available from https://www.secure.cihi.ca/free_products/2011_CORR_Annua_Report_EN.pdf, accessed 18 July 2013

Hill CJ, Fogarty DG (2012) Changing trends in end-stage renal disease due to diabetes in the United Kingdom. J Ren Care 38(Suppl 1):12–22PubMedCrossRef

Sorensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B (2006) Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int 70:187–191PubMedCrossRef

Renal Epidemiology and Information Network (2012) 2010 Annual report. Nephrol Ther 5(Suppl 1):S169–S218

Blotiere PO, Tuppin P, Weill A, Ricordeau P, Allemand H (2010) The cost of dialysis and kidney transplantation in France in 2007; impact of an increase of peritoneal dialysis and transplantation. Nephrol Ther 6:240–247, article in FrenchPubMedCrossRef

10.

Assogba GF, Couchoud C, Roudier C et al (2012) Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and 2007). Diabetes Metab 38:558–566PubMedCrossRef

11.

Bonnet F, Gauthier E, Gin H et al (2011) Expert consensus on management of diabetic patients with impairment of renal function. Diabetes Metab 37(Suppl 2):S1–S25PubMedCrossRef

12.

Ricci P, Blotière PO, Weill A, Simon D, Ricordeau P, Allemand H (2010) Treated diabetes: which trends between 2000 and 2009 in France? Bull Epidémiol Hebd 43:425–431

13.

National Agency for Accreditation and Evaluation in Health Care (2002) Diagnosis of end-stage renal disease in adults. Available from www.has-sante.fr/portail/upload/docs/application/pdf/irc_chez_ladulte_2002-_recommandations.pdf, accessed 18 July 2013

14.

Villar E, Chang SH, McDonald SP (2007) Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991–2005). Diabetes Care 30:3070–3076PubMedCrossRef

15.

Couchoud C, Stengel B, Landais P et al (2006) The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant 21:411–418PubMedCrossRef

16.

van Dijk PC, Jager KJ, de Charro F (2001) Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 16:1120–1129PubMedCrossRef

17.

Bashir S, Esteve J (2000) Analysing the difference due to risk and demographic factors for incidence or mortality. Int J Epidemiol 29:878–884PubMedCrossRef

18.

Locatelli F, Aljama P, Canaud B et al (2010) Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant 25:2846–2850PubMedCrossRef

19.

U.S. Renal Data System (2013) USRDS 2013 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda

20.

Couchoud C, Guihenneuc C, Bayer F, Lemaitre V, Brunet P, Stengel B (2012) Medical practice patterns and socio-economic factors may explain geographical variation of end-stage renal disease incidence. Nephrol Dial Transplant 27:2312–2322PubMedCrossRef

21.

Ward MM (2009) Access to care and the incidence of end-stage renal disease due to diabetes. Diabetes Care 32:1032–1036PubMedCentralPubMedCrossRef

22.

Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004) The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141:95–101PubMedCrossRef

23.

Locatelli F, Pozzoni P, Del Vecchio L (2004) Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 15(Suppl 1):S25–S29PubMedCrossRef

24.

van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD (2005) Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 67:1489–1499PubMedCrossRef

25.

Couchoud C, Guihenneuc C, Bayer F, Stengel B (2010) The timing of dialysis initiation affects the incidence of renal replacement therapy. Nephrol Dial Transplant 25:1576–1578PubMedCentralPubMedCrossRef

26.

Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS (2009) Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 122:443–453PubMedCrossRef

27.

Saaddine JB, Cadwell B, Gregg EW et al (2006) Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144:465–474PubMedCrossRef

28.

Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860PubMedCrossRef

29.

Imperatore G, Cadwell BL, Geiss L et al (2004) Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971–2000. Am J Epidemiol 160:531–539PubMedCrossRef

30.

Fagot-Campagna A, Fosse S, Roudier C et al (2009) Characteristics, vascular risk and complications in people with diabetes, in metropolitan France: major improvements between ENTRED 2001 and ENTRED 2007 studies. Bull Epidémiol Hebd 42–43:450–455

31.

Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544PubMedCrossRef

32.

Brenner BM, Cooper ME, de Zeeuw D (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef

33.

McClellan WM, Flanders WD (2003) Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 14(Suppl 2):S65–S70PubMedCrossRef

34.

Bayat S, Frimat L, Thilly N, Loos C, Briancon S, Kessler M (2006) Medical and non-medical determinants of access to renal transplant waiting list in a French community-based network of care. Nephrol Dial Transplant 21:2900–2907PubMedCrossRef

35.

Lassalle M, Labeeuw M, Frimat L et al (2010) Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. Kidney Int 77:700–707PubMedCrossRef

36.

Ritz E (2005) Managing anaemia and diabetes: a future challenge for nephrologists. Nephrol Dial Transplant 20(Suppl 6):vi21–vi25PubMed

37.

Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G (2005) Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 165:466–469PubMedCrossRef

38.

Thilly N, Stengel B, Boini S, Villar E, Couchoud C, Frimat L (2008) Evaluation and determinants of underprescription of erythropoiesis stimulating agents in pre-dialysis patients with anaemia. Nephron Clin Pract 108:c67–c74PubMedCentralPubMedCrossRef

39.

Kilpatrick RD, Critchlow CW, Fishbane S et al (2008) Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3:1077–1083PubMedCentralPubMedCrossRef

40.

Szczech LA, Barnhart HX, Inrig JK et al (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791–798PubMedCentralPubMedCrossRef

Titel: Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007–2011
verfasst von: Frank G. A. Assogba
Cécile Couchoud
Thierry Hannedouche
Emmanuel Villar
Luc Frimat
Anne Fagot-Campagna
Christian Jacquelinet
Bénédicte Stengel
on behalf of the French Renal Epidemiology and Information Network (REIN) Registry
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 4/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-014-3160-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study

Alternative human liver transcripts of TCF7L2 bind to the gluconeogenesis regulator HNF4α at the protein level

Pleiotropic effects of HNF1A rs1183910 in a population-based study of 60,283 individuals

Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice